Market Overview

Cramer Recommends J&J For Best Big Pharma Pipeline Play

Related JNJ
Johnson & Johnson Shares Might Break Lower Before They Break Out
Johnson & Johnson Shares Strong Since Actelion Acquisition, But Potential For Upside Remains
Brouwer & Janachowski, LLC Buys iShares MSCI Eurozone, JPMorgan Chase, Honeywell ... (GuruFocus)

Coming out of the Twittersphere Wednesday afternoon: a trader asks Jim Cramer about a potential big pharma play which could fit into his or her portfolio. The trader specified the play would need to be for over the next five years. Cramer responded:

J&J (NYSE: JNJ) shares do not seem to be responding to the recommendation by Cramer, but are trading at afternoon highs. The stock is down 0.6 percent to $92.74 at last check.

Posted-In: News Jim Cramer Media Trading Ideas


Related Articles (JNJ)

View Comments and Join the Discussion!